EXAS Add to watchlist
$104.91 +0.00 (+0.00%)
After Hours: $104.91 +0.00 (+0.00%)
Last updated: Apr 15, 2026 22:53
52-Week Range
$104.91
$38.81 $104.91 $104.98

Fundamentals Overview

Exact Sciences Corporation is near the high of its 52-week range with moderate valuation, trading relatively flat today.

Valuation moderate

P/B 8.29 P/S 6.17

Intrinsic value (DCF)

-26.8% downside vs price

Risk (Beta)

1.44 — higher vol

BullzEye Analysis

Our composite tilts Sell on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell
Buy
Sell — 66% confidence Risk: High Volatility — Beta 1.44. Consider smaller position size due to higher beta.

Supporting (Buy):

3M vs Healthcare sector: +8.7%

Pressures (Sell):

DCF 26.8% downside vs price · Sentiment weakening (11 downgrades) · Beta 1.44 (elevated)

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap
$20.03B
P/E (TTM)
N/A
EPS (TTM)
N/A
Dividend Yield
N/A
52-Week Range
$38.81 - $104.98
Volume vs Avg
N/A
Beta
1.44

About

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metast...
Sector: Healthcare
Headquarters: US
Employees: 6,900
IPO Date: Feb 2001
Beta: 1.44 (More volatile than market)

Ratings & Grades at a Glance

Recent institutional grades: majority downgrades. Current institutional positions: Buy: 8, Equal Weight: 2, Hold: 4, In Line: 1, Market Perform: 1, Neutral: 4, Outperform: 3, Overweight: 6, Sector Perform: 1.

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

DCF vs price: DCF estimate is $76.77; current price is $104.91. That’s a -26.8% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.

Metric Value
Valuation
P/E (TTM) N/A
DCF value (model) $76.77 (-26.8% vs price)
PEG (TTM) N/A
P/B (TTM) 8.29
P/S (TTM) 6.17
P/FCF (TTM) 56.13
Liquidity & enterprise
Current Ratio (TTM) 2.23
Quick Ratio (TTM) 1.97
Cash Ratio (TTM) 1.49
Profitability
ROE (TTM) N/A
ROA (TTM) N/A
Revenue growth (YoY) N/A
Net margin (TTM) -6.4%
Gross margin (TTM) 69.69%
Operating margin (TTM) -6.17%
Debt to equity (TTM) N/A

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for EXAS.

Analyst Sentiment at a Glance

Sentiment Weakening
Buy 8Equal Weight 2Hold 4In Line 1Market Perform 1Neutral 4Outperform 3Overweight 6Sector Perform 1
0 upgrades, 11 downgrades
Price Target Consensus
Current $104.91
Median $105.00
Consensus $103.18
Low consensus $85.00
High consensus $105.00

Stock Grades (Institutions)

Institution Action Previous Grade New Grade Date
Mizuho downgrade Outperform Neutral 2026-01-20
Evercore ISI Group downgrade Outperform In Line 2026-01-05
Stifel downgrade Buy Hold 2025-11-28
Canaccord Genuity downgrade Buy Hold 2025-11-25
Jefferies downgrade Buy Hold 2025-11-24
Benchmark downgrade Buy Hold 2025-11-24
Wells Fargo downgrade Overweight Equal Weight 2025-11-21
William Blair downgrade Outperform Market Perform 2025-11-21
Barclays downgrade Overweight Equal Weight 2025-11-21
Guggenheim downgrade Buy Neutral 2025-11-21
BTIG downgrade Buy Neutral 2025-11-20
Piper Sandler maintain Overweight Overweight 2025-11-11
Wells Fargo maintain Overweight Overweight 2025-11-05
BTIG maintain Buy Buy 2025-11-04
Stifel maintain Buy Buy 2025-11-04
Benchmark maintain Buy Buy 2025-11-04
Guggenheim maintain Buy Buy 2025-11-04
Barclays maintain Overweight Overweight 2025-11-04
Baird maintain Outperform Outperform 2025-11-04
TD Cowen maintain Buy Buy 2025-11-04
BTIG maintain Buy Buy 2025-10-22
Piper Sandler maintain Overweight Overweight 2025-10-08
Evercore ISI Group maintain Outperform Outperform 2025-10-07
Barclays maintain Overweight Overweight 2025-10-02
Craig-Hallum maintain Buy Buy 2025-09-11
BTIG maintain Buy Buy 2025-08-12
Piper Sandler maintain Overweight Overweight 2025-08-11
Evercore ISI Group maintain Outperform Outperform 2025-08-08
UBS maintain Neutral Neutral 2025-08-07
RBC Capital maintain Sector Perform Sector Perform 2025-08-07